Financial Data and Key Metrics Changes - Total global net sales in Q4 reached $218.6 million, a 3% increase supported by strong performances in Bone Growth Therapies and U.S. limb reconstruction segments [13] - Pro forma non-GAAP Adjusted EBITDA was $29.2 million, or 13.4% of net sales, with year-over-year margin expansion of approximately 230 basis points [15] - Free cash flow for Q4 was exceptionally strong at $16.8 million, demonstrating the strength and scalability of the business model [15] Business Line Data and Key Metrics Changes - Bone Growth Therapies (BGT) net sales were $68.3 million, up 7%, significantly outperforming the market [14] - U.S. Limb Reconstruction sales were $38 million in Q4, driven by 8% U.S. growth [14] - Global spine fixation Q4 net sales grew 10% for the year and in Q4, with U.S. spine fixation net sales growing 6% for the year and 5% for the quarter [4][5] Market Data and Key Metrics Changes - U.S. Limb Reconstruction grew 8% in Q4 and 16% for the full year, driven by successful product launches [7] - The BGT business delivered strong sequential fourth quarter growth, reaching 7%, more than double the market rate [8] - The company expects to return to double-digit growth in the second half of 2026 for U.S. Limb Reconstruction as portfolio refinements take hold [14] Company Strategy and Development Direction - The company has rebranded its orthopedics business as Limb Reconstruction, focusing on high-value clinical categories with an estimated $2.6 billion market opportunity [6] - The full market release of the VIRATA Spinal Fixation System is anticipated in the second half of 2026, expected to enhance surgical efficiency and serve as a growth catalyst [6] - The company is recalibrating its three-year financial targets to fully capture the anticipated benefits of its spine commercial channel optimization, extending the timeline to 2028 [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a solid foundation for growth, driven by a focused distributor network and innovation pipeline [11][25] - The company is committed to disciplined execution and targeted capital deployment to create sustainable long-term shareholder value [24][27] - Management highlighted the importance of ongoing product launches and enhancements across all business segments to drive sustained momentum [26] Other Important Information - The company expects full-year net sales of $850 million-$860 million for 2026, representing implied pro forma constant currency year-over-year growth of approximately 5.5% [17] - Adjusted gross margins for the full year 2026 are expected to be approximately 72.5% [18] - The company anticipates $45 million-$50 million in capital expenditures for the year [22] Q&A Session Summary Question: Clarification on CMS impact on BGT - Management clarified that the CMS change will have about a 1% impact in Q1 specific to BGT revenue only [32] Question: Long-range plan and margin improvement - Management explained that the extended timeline reflects the need for a stronger foundation and focus on market execution, with ongoing efforts to improve gross margins and cash generation [34][37] Question: 2026 revenue guidance specifics - Management expects above-market growth for BGT and limb reconstruction, with a return to double-digit growth in the second half of 2026 for limb reconstruction [42] Question: 7D placements and biologics portfolio - Management reported a 30% increase in 7D placements in 2025 and emphasized a renewed focus on advancing the biologics portfolio [51][52] Question: Tariff impact and legal settlements - Management indicated an expected $1 million-$2 million impact from tariffs in 2026 and confirmed that an accrual for a legal settlement was taken in Q3 [57][62]

Financial Data and Key Metrics Changes - The company reported solid operating and financial performance for Q4 and full-year 2024, achieving 4.5% consolidated organic growth driven by demand across towers, small cells, and fiber solutions [39][47] - Structural reductions in operating costs of $100 million on an annualized basis and a reduction in net CapEx by almost $200 million compared to the revised 2024 full-year forecast were achieved [16][39] - A goodwill impairment charge of approximately $5 billion was recorded for the full-year 2024 due to the carrying amount of the Fiber Reporting unit exceeding its estimated fair value [20] Business Line Data and Key Metrics Changes - Organic growth in towers was 4.5%, small cells 12%, and fiber solutions 2%, with small cells achieving the highest level of incremental annual node production in the company's history [17][18] - The company plans to focus on free cash flow generation rather than topline revenue growth, increasing the hurdle rates for project pipelines and enhancing capital spending efficiency [13][16] Market Data and Key Metrics Changes - The company anticipates a continuation of solid growth in 2025, projecting organic growth of 4.5% in towers, excluding the impact of Sprint consolidation churn [22][23] - The expected churn rate for towers remains between 1% to 2%, with approximately $205 million in Sprint churn anticipated [25][26] Company Strategy and Development Direction - The company has concluded its fiber strategic review and signed a definitive agreement to sell its Fiber segment to EQT and Zayo, aiming to maximize long-term shareholder value by focusing on its tower business [7][9] - The capital allocation framework will prioritize free cash flow generation, with plans to return capital to shareholders through dividends and share repurchases post-transaction [30][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term strength of the tower business model, highlighting the U.S. as the best market for wireless infrastructure ownership [48] - The company expects to maintain an investment-grade credit rating post-transaction, targeting leverage between 6 times and 6.5 times [33][89] Other Important Information - The company plans to implement a share repurchase program of approximately $3 billion in conjunction with the close of the fiber transaction, expected in the first half of 2026 [34][34] - The company will continue to operate the Fiber segment in the ordinary course of business during 2025, expecting it to generate results in line with 2024 [21][76] Q&A Session Summary Question: Is the company locked into the U.S. market for towers, or might it consider opportunities in Europe? - The company is focused on the U.S. market but remains open to evaluating inbound opportunities if they arise [55][58] Question: What is the expected organic growth for the tower business? - The company projects 4.5% growth in the tower business, with dividend growth expected to mirror AFFO growth over time [61][62] Question: Can you provide insights on leasing activity and capital allocation? - The company has seen a sequential increase in applications, primarily driven by carrier deployments of mid-band spectrum, and anticipates stable revenue visibility due to master lease agreements [70][72] Question: What is the expected free cash flow contribution from the Fiber segment? - The Fiber segment is expected to generate approximately $250 million in positive free cash flow for 2025, similar to 2024 levels [76] Question: What are the plans for capital expenditures and operational initiatives? - The company plans to allocate capital towards land acquisition and improving operational efficiencies, with a focus on enhancing margins and customer service [128][135]